Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB-SZTN Cause Mobility decreased? 52 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 52 reports of Mobility decreased have been filed in association with NATALIZUMAB-SZTN. This represents 27.7% of all adverse event reports for NATALIZUMAB-SZTN.

52
Reports of Mobility decreased with NATALIZUMAB-SZTN
27.7%
of all NATALIZUMAB-SZTN reports
0
Deaths
0
Hospitalizations

How Dangerous Is Mobility decreased From NATALIZUMAB-SZTN?

Of the 52 reports.

Is Mobility decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB-SZTN. However, 52 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB-SZTN Cause?

Fatigue (63) Balance disorder (31) Headache (18) Product substitution issue (17) Multiple sclerosis relapse (16) Muscular weakness (16) Cognitive disorder (13) Gait disturbance (13) Dizziness (11) Nausea (9)

What Other Drugs Cause Mobility decreased?

ADALIMUMAB (8,829) ETANERCEPT (8,321) METHOTREXATE (5,936) ABATACEPT (4,519) TOCILIZUMAB (4,403) LEFLUNOMIDE (4,354) HYDROXYCHLOROQUINE (4,105) RITUXIMAB (4,067) INFLIXIMAB (3,784) TOFACITINIB (3,734)

Which NATALIZUMAB-SZTN Alternatives Have Lower Mobility decreased Risk?

NATALIZUMAB-SZTN vs NATAMYCIN NATALIZUMAB-SZTN vs NATEGLINIDE NATALIZUMAB-SZTN vs NAVITOCLAX NATALIZUMAB-SZTN vs NAXITAMAB-GQGK NATALIZUMAB-SZTN vs NEBIVOLOL

Related Pages

NATALIZUMAB-SZTN Full Profile All Mobility decreased Reports All Drugs Causing Mobility decreased NATALIZUMAB-SZTN Demographics